DUBLIN–(BUSINESS WIRE)–The “Clinical Quality Management Systems Training Course (Mar 23rd – Mar 24th, 2026)” training has been added to ResearchAndMarkets.com’sDUBLIN–(BUSINESS WIRE)–The “Clinical Quality Management Systems Training Course (Mar 23rd – Mar 24th, 2026)” training has been added to ResearchAndMarkets.com’s

Pharma and Medical Device Clinical Quality Management Systems Training Course: EMA Guidance on Computerised Systems and ICH GCP R3 Data Governance (Mar 23rd – Mar 24th, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Clinical Quality Management Systems Training Course (Mar 23rd – Mar 24th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

This course will provide essential information and guidance to help you achieve regulatory compliance in this evolving area of clinical quality, including EMA guidance on computerised systems and ICH GCP R3 data governance.

With increasing clinical quality standards required by inspectors, there is currently no harmonised regulatory guidance for clinical quality management systems (CQMS), although there are multiple documents from different sources across the pharmaceutical and medical device industries.

The regulators however, both in Europe and the US, expect an effective QMS to be in place for clinical development. Organisations are struggling to effectively implement and integrate these QMS standards, including ISO 9000 principles, ICH10 for CQMS and ICH GCP R2 and R3 CQMS requirements.

Who Should Attend:

This course is aimed at anyone working in clinical research or associated functions, including regulatory affairs and document management, who needs to know how to establish, maintain, monitor and improve a CQMS that focuses on product quality and compliance to GCP.

The programme will also be of value to those working in quality assurance and quality improvement roles in clinical research, management responsible for governance of CQMS and anyone working with or in clinical research who needs to comply with the new requirements for CQMS, including study sites.

It is ideal for those implementing a CQMS, those wanting to share best practice and anyone wanting an update on new developments in this area.

Benefits of attending:

  • Understand developing regulatory requirements for clinical quality management systems (CQMS)
  • Review proposed CQMS framework
  • Consider best practice in key CQMS areas

Certification:

  • CPD: 12 hours for your records
  • Certificate of completion

Key Topics Covered:

Day 1

What is clinical quality and CQMS?

  • Quality principles and definitions
  • Proposed CQMS framework

New industry CQMS framework

  • The components of a CQMS
  • Quality by design – what does it mean and how does it apply to clinical research and the CQMS?

QMS – compliance deficiencies

  • What are inspectors looking for?
  • Feedback from the regulators – hot inspection topics and trends
  • Balancing strict regulations and progress in research

Documentation supporting CQMS

Enrol or reserve

Day 2

Importance of KPIs in your QMS and governance

  • Documentation of KPIs and key performance tolerance levels
  • Quality tolerance limits (QTL)
  • Management review and governance of a CQMS

Risk-based component of CQMS

  • Risk methodologies to include in CQMS
  • ICH GCP R2 and R3 risk-based elements of a CQMS

Vendor oversight

  • Outsourcing and partnership
  • Demonstrating and documenting vendor oversight to inspectors
  • Metrics and KPIs

Issues and CAPA management

  • Correction, corrective action, preventive action and root cause analysis

Key consideration for computer systems and governance and validation

  • Essentials of validation
  • EMA guidance on computer systems
  • ICH GCP R3 governance
  • What are inspectors looking for?
  • AI

QMS – technology solutions

  • Examples of technology solutions and support technologies for CQMS

Speakers:

Laura Brown

Pharmaceutical QA and Training Consultant

University of Cardiff

Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years’ experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International.

She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including “The Planning of International Drug Development”, in the Clinical Research Manual, Euromed and the “Impact of Brexit”, RQA Journal 2017.

For more information about this training visit https://www.researchandmarkets.com/r/wliwzl

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
Areon Network Logo
Areon Network Price(AREA)
$0.01631
$0.01631$0.01631
+29.44%
USD
Areon Network (AREA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Strategy Buys $109M in Bitcoin as Corporate BTC Treasuries Expand in 2025

Strategy Buys $109M in Bitcoin as Corporate BTC Treasuries Expand in 2025

The post Strategy Buys $109M in Bitcoin as Corporate BTC Treasuries Expand in 2025 appeared on BitcoinEthereumNews.com. Strategy announced its latest Bitcoin purchase
Share
BitcoinEthereumNews2025/12/30 08:46
Tokyo Fashion Brand Expands Into Bitcoin and AI

Tokyo Fashion Brand Expands Into Bitcoin and AI

The post Tokyo Fashion Brand Expands Into Bitcoin and AI appeared on BitcoinEthereumNews.com. On Wednesday, Japanese casual apparel retailer Mac House announced that shareholders approved a name change to Gyet Co., Ltd., signaling a strategic shift into crypto and digital assets. The move highlights a broader corporate plan centered on cryptocurrency, blockchain, and artificial intelligence. It reflects the company’s ambition to launch a global Bitcoin treasury program, drawing attention from both domestic and international observers. “Yet” and Its Global Significance Gyet’s amended corporate charter introduces wide-ranging digital initiatives, adding cryptocurrency acquisition, trading, management, and payment services. The new objectives also cover crypto mining, staking, lending, and yield farming, as well as blockchain system development, NFT-related projects, and research in generative AI and data center operations. These changes indicate a clear intent to diversify beyond apparel and position the company within global technology and finance sectors. Sponsored Sponsored The rebranding reflects Gyet’s aim to operate with a broader international outlook. Its new name conveys three concepts: “Growth Yet,” “Global Yet,” and “Generation Yet,” signaling a desire to create technology-driven value for future generations while expanding beyond Japan’s domestic market. Bitcoin Purchasing and Mining Gyet declared its digital asset ambitions in June 2025 and in July signed a basic cooperation agreement with mining firm Zerofield. The company has since begun a $11.6 million Bitcoin acquisition program and is testing mining operations in US states such as Texas and Georgia, where electricity costs are relatively low. Its goal of holding more than 1,000 BTC is modest globally, but the model—funding purchases and mining with retail cash flow—remains unusual for an apparel business. Within Japan, Gyet follows companies such as Hotta Marusho and Kitabo, which have also diversified into cryptocurrency activities distinct from their original operations. This move may accelerate corporate Bitcoin holdings as a financial strategy, attract interest in overseas mining ventures by Japanese firms, and…
Share
BitcoinEthereumNews2025/09/18 11:13
Scaramucci: Solana Could Surpass Ethereum Market Cap on Growth, Activity

Scaramucci: Solana Could Surpass Ethereum Market Cap on Growth, Activity

The post Scaramucci: Solana Could Surpass Ethereum Market Cap on Growth, Activity appeared on BitcoinEthereumNews.com. Anthony Scaramucci predicts Solana could
Share
BitcoinEthereumNews2025/12/30 09:38